Artelo Biosciences
ARTL
5 hedge funds and large institutions have $37.2K invested in Artelo Biosciences in 2024 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.
25% more funds holding
Funds holding: 4 → 5 (+1)
8% more capital invested
Capital invested by funds: $34.4K → $37.2K (+$2.82K)
0% less ownership
Funds ownership: 0.04% → 0.04% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$186 |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$80 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$27 |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
-$9 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
Geode Capital Management
Boston,
Massachusetts
| $29.7K | – | – | – |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $7.21K | +$80 | +3 | +1% |
|
|
3
UBS Group
Zurich,
Switzerland
| $185 | +$186 | +7 | New |
|
4
Wells Fargo
San Francisco,
California
| $37 | – | – | – |
|
|
5
Morgan Stanley
New York
| $30 | -$27 | -1 | -50% |
|
|
RIL
6
Rothschild Investment LLC
Chicago,
Illinois
| $12 | – | – | – |
|
|
NA
7
NewEdge Advisors
New Orleans,
Louisiana
| $1 | – | – | – |
|
|
8
Osaic Holdings
Scottsdale,
Arizona
| – | -$9 | – | – |
|
ARTL Hedge Fund Activity: Q1 2024 in Review
5 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in Artelo Biosciences (ARTL) for Q1 2024, worth a combined $37.2K — up 8.2% from $34.4K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new ARTL positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was UBS Group, opening a new position worth an estimated $186. The largest seller was Morgan Stanley, cutting an estimated $27.
- 5 institutional investors held Artelo Biosciences (ARTL) as of Q1 2024, up from 4 in Q4 2023.
- Funds reported $37.2K of Artelo Biosciences stock for Q1 2024, up 8.2% quarter-over-quarter.
- 1 fund opened new Artelo Biosciences positions in Q1 2024 and 0 closed out, a net change of +1 holder.
- The largest Artelo Biosciences buyer in Q1 2024 was UBS Group, an estimated $186 added.
- The largest Artelo Biosciences seller in Q1 2024 was Morgan Stanley, an estimated $27 sold.
Based on aggregated 13F filings for Q1 2024.